How ETI therapy affects body and gut in cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis (CF).
- You are about to start taking the triple combination therapy (ETI) for the first time.
- You are willing to provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.
This study looks at how the medicine elexacaftor/tezacaftor/ivacaftor (often called Trikafta) works in the body in people with cystic fibrosis. It helps doctors understand the right dose and how the drug is processed, which may improve treatment for children and adults.
This study looks at how the drug Trikafta (also called Kaftrio) works in children aged 2 to 17 with cystic fibrosis. The goal is to learn how the body processes the medicine so doctors can find the best dose.
This study tests whether a special nutrition supplement can improve health in adults with cystic fibrosis and pancreatic insufficiency who are already on a modulator therapy. The goal is to see if the supplement helps with digestion and overall well-being.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.